Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Logical Therapeutics has completed its Phase Ib randomized controlled multi-dose safety and pharmacokinetics study of LT-NS001, the company's proprietary naproxen prodrug.
Subscribe to our email newsletter
The study, which was conducted in normal adult volunteers, showed that LT-NS001 was well-tolerated by the recipients. Moreover, when the subjects in the study were dosed twice daily with LT-NS001 for seven days, plasma concentrations of naproxen were within the therapeutic range.
LT-NS001 is a prodrug, which is converted in the bloodstream into naproxen, a non-steroidal anti-inflammatory drug. The company expects to begin enrolling subjects in its next clinical study of LT-NS001 later 2008.
Mitchell Fink, president and CEO of Logical Therapeutics, said: “The results from our recently completed Phase Ib study of LT-NS001 are very encouraging, because they show that administration of the pro-drug leads to clinically useful circulating levels of naproxen.”